文献速递血液净化与透析

药物涂层球囊在失功动静脉内瘘中的随机对照试验

Drug Coated Balloon Angioplasty in Failing AV Fistulas: A Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-07-24

这项多中心随机试验纳入285例失功动静脉内瘘患者,比较紫杉醇涂层球囊与传统球囊血管成形术。180天靶病变主要通畅率分别为71%±4%和63%±4%(P=0.06),未达主要有效性终点;30天安全性非劣效终点达标(P=0.002)。

要点

  • 药物涂层球囊未显著提高180天靶病变主要通畅率(71%±4% vs 63%±4%,P=0.06)。
  • 6个月内药物涂层球囊组维持靶病变通畅的再干预次数更少(0.31 vs 0.44次/人,P=0.03)。
  • 30天安全性非劣效终点达标,两组间无差异(P=0.002)。

核心结论

  • 紫杉醇涂层球囊辅助血管成形术在180天时未达到优于传统球囊的主要有效性终点。

研究设计与样本

  • 多中心随机对照试验,纳入285例失功动静脉内瘘患者,分布于23个中心。
  • 排除移植物、中心静脉狭窄、血栓性内瘘及未成熟内瘘。
  • 所有患者先接受病变血管成形术,残余狭窄≤30%后随机接受紫杉醇涂层球囊或无涂层对照球囊治疗。

主要发现

  • 180天靶病变主要通畅率:药物涂层球囊组71%±4%,对照组63%±4%,P=0.06,差异8%±6%(95%CI -3%至20%)。
  • 6个月通路回路主要通畅率两组无差异。
  • 6个月内维持靶病变通畅的再干预次数:药物涂层球囊组0.31次/人,对照组0.44次/人,P=0.03。
  • 30天安全性非劣效终点达标,两组无差异(P=0.002)。

临床怎么用

  • 对于失功动静脉内瘘,紫杉醇涂层球囊未显示180天靶病变主要通畅率优势,但可减少6个月内再干预次数。
  • 安全性在30天内与传统球囊相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Restenosis remains a problem in hemodialysis access interventions. Paclitaxel-coated balloons have shown promise in reducing access-related restenosis in small trials. The primary hypotheses for our multicenter trial were superior effectiveness at 180 days and noninferior safety at 30 days of a drug-coated balloon compared with conventional angioplasty for treatment of dysfunctional arteriovenous fistulas. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This randomized trial enrolled 285 patients with dysfunctional arteriovenous fistulas at 23 centers. Grafts, central venous stenoses, thrombosed fistulas, and immature fistulas were excluded. All patients received angioplasty of the lesion responsible for access dysfunction. After successful angioplasty (≤30% residual stenosis), lesions were treated with either a paclitaxel-coated balloon or an uncoated control balloon of similar design to the drug-coated balloon. Access function during follow-up was determined per centers' usual protocols; reintervention was clinically driven. The primary efficacy outcome assessment was done at 6 months, and the safety assessment was done within 30 days of the procedure. Prespecified secondary end points included assessment of postintervention target lesion primary patency and access circuit primary patency at 6 months. RESULTS: The 180-day end point was not met with target lesion primary patency (71%±4% for the drug-coated balloon and 63%±4% for control; P=0.06), representing a difference of 8%±6% (95% confidence interval, -3% to 20%). Access circuit primary patency did not differ between groups. Interventions to maintain target lesion patency were fewer for the drug-coated balloon at 6 months (0.31 versus 0.44 per patient; P=0.03). The primary safety noninferiority end point was met and did not differ between groups (P=0.002). CONCLUSIONS: Paclitaxel-coated balloon-assisted angioplasty did not meet the primary effectiveness end point at 180 days compared with conventional angioplasty. Both arms showed equivalent safety (ClinicalTrials.gov number NCT02440022).

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Trerotola SO, Lawson J, Roy-Chaudhury P, et al. Drug Coated Balloon Angioplasty in Failing AV Fistulas: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2018. PMID: 30042225. doi:10.2215/CJN.14231217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。